1
|
Han B, Yue F, Zhang X, Xu K, Zhang Z, Sun Z, Mu L, Li X. Genetically engineering of Saccharomyces cerevisiae for enhanced oral delivery vaccine vehicle. FISH & SHELLFISH IMMUNOLOGY 2024; 146:109425. [PMID: 38316348 DOI: 10.1016/j.fsi.2024.109425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2023] [Revised: 01/24/2024] [Accepted: 02/02/2024] [Indexed: 02/07/2024]
Abstract
As a series of our previous studies reported, recombinant yeast can be the oral vaccines to deliver designed protein and DNA, as well as functional shRNA, into dendritic cells (DCs) in mice for specific immune regulation. Here, we report the further optimization of oral yeast-based vaccine from two aspects (yeast characteristics and recombinant DNA constitution) to improve the effect of immune regulation. After screening four genes in negative regulation of glucan synthesis in yeast (MNN9, GUP1, PBS2 and EXG1), this research combined HDR-based genome editing technology with Cre-loxP technology to acquire 15 gene-knockout strains without drug resistance-gene to exclude biosafety risks; afterward, oral feeding experiments were performed on the mice using 15 oral recombinant yeast-based vaccines constructed by the gene-knockout strains harboring pCMV-MSTN plasmid to screen the target strain with more effective inducing mstn-specific antibody which in turn increasing weight gain effect. And subsequently based on the selected gene-knockout strain, the recombinant DNA in the oral recombinant yeast-based vaccine is optimized via a combination of protein fusion expression (OVA-MSTN) and interfering RNA technology (shRNA-IL21), comparison in terms of both weight gain effect and antibody titer revealed that the selected gene-knockout strain (GUP1ΔEXG1Δ) combined with specific recombinant DNA (pCMV-OVA-MSTN-shIL2) had a better effect of the vaccine. This study provides a useful reference to the subsequent construction of a more efficient oral recombinant yeast-based vaccine in the food and pharmaceutical industry.
Collapse
Affiliation(s)
- Baoquan Han
- Department of Urology, Shenzhen University General Hospital, Shenzhen, 518055, China; College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China
| | - Feng Yue
- College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China
| | - Xiaojun Zhang
- College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China
| | - Kun Xu
- College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China
| | - Zhiying Zhang
- College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China.
| | - Zhongyi Sun
- Department of Urology, Shenzhen University General Hospital, Shenzhen, 518055, China.
| | - Lu Mu
- College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China
| | - Xiaoyu Li
- College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China
| |
Collapse
|
2
|
Yue F, Du L, Wang R, Han B, Zhang X, Yao Z, Zhang W, Cai C, Zhang Z, Xu K. In vivo Protein Interference: Oral Administration of Recombinant Yeast-Mediated Partial Leptin Reduction for Obesity Control. Front Microbiol 2022; 13:923656. [PMID: 35774455 PMCID: PMC9237534 DOI: 10.3389/fmicb.2022.923656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 05/17/2022] [Indexed: 12/17/2022] Open
Abstract
Obesity-related diseases are always the major health problems that concern the whole world. Serial studies have reported that obesity development is closely related to the out-of-control leptin encoded by the obesity gene (ob). The latest report declaimed “Less Is More,” a model explaining that partial leptin reduction triggers leptin sensitization and contributes to obesity control. Here, we came up with a novel concept, in vivo protein interference (iPRTi), an interesting protein knock-down strategy for in vivo partial leptin reduction. First, the specific immune response against leptin induced by the oral administration of ob recombinant yeast was confirmed. Subsequentally, leptin resistance was observed in diet-induced obese mice, and oral administration with ob recombinant yeast declined the circulating leptin and reduced significantly the body weight gain. To further investigate whether the iPRTi strategy is capable of obesity management, the diet-induced obese mice were administrated with ob recombinant yeast. All the indexes examined including the circulating leptin, triglyceride, and total cholesterol, as well as food intake and weight gain, demonstrated a positive effect of the iPRTi strategy on obesity control. In short, this study provides a novel strategy for the potential application of recombinant yeast for the therapy of obese individuals with leptin resistance.
Collapse
|
3
|
Duman-Scheel M. Saccharomyces cerevisiae (Baker's Yeast) as an Interfering RNA Expression and Delivery System. Curr Drug Targets 2020; 20:942-952. [PMID: 30474529 PMCID: PMC6700756 DOI: 10.2174/1389450120666181126123538] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Revised: 11/15/2018] [Accepted: 11/15/2018] [Indexed: 11/22/2022]
Abstract
The broad application of RNA interference for disease prevention is dependent upon the production of dsRNA in an economically feasible, scalable, and sustainable fashion, as well as the identification of safe and effective methods for RNA delivery. Current research has sparked interest in the use of Saccharomyces cerevisiae for these applications. This review examines the potential for commercial development of yeast interfering RNA expression and delivery systems. S. cerevisiae is a genetic model organism that lacks a functional RNA interference system, which may make it an ideal system for expression and accumulation of high levels of recombinant interfering RNA. Moreover, recent studies in a variety of eukaryotic species suggest that this microbe may be an excellent and safe system for interfering RNA delivery. Key areas for further research and development include optimization of interfering RNA expression in S. cerevisiae, industrial-sized scaling of recombinant yeast cultures in which interfering RNA molecules are expressed, the development of methods for large-scale drying of yeast that preserve interfering RNA integrity, and identification of encapsulating agents that promote yeast stability in various environmental conditions. The genetic tractability of S. cerevisiae and a long history of using this microbe in both the food and pharmaceutical industry will facilitate further development of this promising new technology, which has many potential applications of medical importance.
Collapse
Affiliation(s)
- Molly Duman-Scheel
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, South Bend, IN, United States
| |
Collapse
|
4
|
Dowaidar M, Abdelhamid HN, Hällbrink M, Freimann K, Kurrikoff K, Zou X, Langel Ü. Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. Sci Rep 2017; 7:9159. [PMID: 28831162 PMCID: PMC5567346 DOI: 10.1038/s41598-017-09803-z] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Accepted: 07/28/2017] [Indexed: 12/26/2022] Open
Abstract
Magnetic nanoparticles (MNPs, Fe3O4) incorporated into the complexes of cell penetrating peptides (CPPs)-oligonucleotides (ONs) promoted the cell transfection for plasmid transfection, splice correction, and gene silencing efficiencies. Six types of cell penetrating peptides (CPPs; PeptFect220 (denoted PF220), PF221, PF222, PF223, PF224 and PF14) and three types of gene therapeutic agents (plasmid (pGL3), splicing correcting oligonucleotides (SCO), and small interfering RNA (siRNA) were investigated. Magnetic nanoparticles incorporated into the complexes of CPPs-pGL3, CPPs-SCO, and CPPs-siRNA showed high cell biocompatibility and efficiently transfected the investigated cells with pGL3, SCO, and siRNA, respectively. Gene transfer vectors formed among PF14, SCO, and MNPs (PF14-SCO-MNPs) showed a superior transfection efficiency (up to 4-fold) compared to the noncovalent PF14-SCO complex, which was previously reported with a higher efficiency compared to commercial vector called Lipofectamine™2000. The high transfection efficiency of the new complexes (CPPs-SCO-MNPs) may be attributed to the morphology, low cytotoxicity, and the synergistic effect of MNPs and CPPs. PF14-pDNA-MNPs is an efficient complex for in vivo gene delivery upon systemic administration. The conjugation of CPPs-ONs with inorganic magnetic nanoparticles (Fe3O4) may open new venues for selective and efficient gene therapy.
Collapse
Affiliation(s)
- Moataz Dowaidar
- Department of Neurochemistry, Stockholm University, Svante Arrhenius väg 16B, Stockholm, SE-10691, Sweden.
| | - Hani Nasser Abdelhamid
- Department of Materials and Environmental Chemistry, Stockholm University, Svante Arrhenius väg 16C, Stockholm, SE-106 91, Sweden
| | - Mattias Hällbrink
- Department of Neurochemistry, Stockholm University, Svante Arrhenius väg 16B, Stockholm, SE-10691, Sweden
| | - Krista Freimann
- Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse, Tartu, 50411, Estonia
| | - Kaido Kurrikoff
- Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse, Tartu, 50411, Estonia
| | - Xiaodong Zou
- Department of Materials and Environmental Chemistry, Stockholm University, Svante Arrhenius väg 16C, Stockholm, SE-106 91, Sweden.
| | - Ülo Langel
- Department of Neurochemistry, Stockholm University, Svante Arrhenius väg 16B, Stockholm, SE-10691, Sweden.
- Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse, Tartu, 50411, Estonia.
| |
Collapse
|
5
|
Roohvand F, Shokri M, Abdollahpour-Alitappeh M, Ehsani P. Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines. Expert Opin Ther Pat 2017; 27:929-951. [PMID: 28608761 DOI: 10.1080/13543776.2017.1339789] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Yeasts, as Eukaryotes, offer unique features for ease of growth and genetic manipulation possibilities, making it an exceptional microbial host. Areas covered: This review provides general and patent-oriented insights into production of biopharmaceuticals by yeasts. Patents, wherever possible, were correlated to the original or review articles. The review describes applications of major GRAS (generally regarded as safe) yeasts for the production of therapeutic proteins and subunit vaccines; additionally, immunomodulatory properties of yeast cell wall components were reviewed for use of whole yeast cells as a new vaccine platform. The second part of the review will discuss yeast- humanization strategies and innovative applications. Expert opinion: Biomedical applications of yeasts were initiated by utilization of Saccharomyces cerevisiae, for production of leavened (fermented) products, and advanced to serve to produce biopharmaceuticals. Higher biomass production and expression/secretion yields, more similarity of glycosylation patterns to mammals and possibility of host-improvement strategies through application of synthetic biology might enhance selection of Pichia pastoris (instead of S. cerevisiae) as a host for production of biopharmaceutical in future. Immunomodulatory properties of yeast cell wall β-glucans and possibility of intracellular expression of heterologous pathogen/tumor antigens in yeast cells have expanded their application as a new platform, 'Whole Yeast Vaccines'.
Collapse
Affiliation(s)
- Farzin Roohvand
- a Department of Virology , Pasteur Institute of Iran , Pasteur Ave, Tehran , Iran
| | - Mehdi Shokri
- a Department of Virology , Pasteur Institute of Iran , Pasteur Ave, Tehran , Iran.,b Department of Immunology , Pasteur Institute of Iran , Tehran , Iran
| | | | - Parastoo Ehsani
- c Department of Molecular Biology , Pasteur Institute of Iran , Tehran , Iran
| |
Collapse
|